Status:
RECRUITING
Evaluating Response to Vitamin D3 and K2 Supplementation in Healthcare Personnel
Lead Sponsor:
Madigan Army Medical Center
Conditions:
Hypovitaminosis D
Hypovitaminosis
Eligibility:
All Genders
18-69 years
Phase:
NA
Brief Summary
The main purpose of this research study is to learn about the effects of supplemental vitamin D3 and vitamin K2 on blood levels and the gut microbial community, called the gut microbiome. There are ma...
Detailed Description
Health promotion efforts for all branches of Service aim to ensure the health and readiness of the Force. This timely, relevant study supports this effort as well as the TriService Nursing Research Pr...
Eligibility Criteria
Inclusion
- able to read and understand English
- 25 OHD serum level equal to or less than 30 ng/mL
- willing to discontinue vitamin D3 and/or K2 supplements for 4.5 months
- military beneficiary (Active Duty, Retired, Dependent)
- remaining employed at workplace for 6 months
Exclusion
- Diagnosed medical condition that prevents nutrient absorption from food (e.g. Inflammatory Bowel Disease, Celiac Disease, post-Roux-en-Y/Gastric sleeve surgery)
- Pregnant or breastfeeding
- Current antibiotic use or within past 3 months
- Current anticoagulant use or within past 3 months
- Current weight loss or fat malabsorption medication use (e.g. Glucagon-Like Peptide 1 agonists, Orlistat)
- Allergies or sensitivities to methylcellulose, vitamin D (D3, D2), or vitamin K (K2, Menaquinone-4, Menaquinone-7)
Key Trial Info
Start Date :
March 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT07199829
Start Date
March 27 2025
End Date
March 1 2026
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Madigan Army Medical Center
Tacoma, Washington, United States, 98431